Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joint ( (JYNT) ) has issued an announcement.
On September 30, 2025, Joint company entered into a consent and third amendment to its existing credit agreement with JPMorgan Chase Bank. This amendment includes the lender’s consent to the refranchising of all company-owned or managed clinics and extends the revolving credit maturity date to August 31, 2027, potentially impacting the company’s operational flexibility and financial strategy.
The most recent analyst rating on (JYNT) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Joint stock, see the JYNT Stock Forecast page.
Spark’s Take on JYNT Stock
According to Spark, TipRanks’ AI Analyst, JYNT is a Neutral.
The overall stock score is primarily influenced by financial performance challenges, including consistent net losses and cash flow sustainability issues. While technical indicators suggest bearish momentum, recent corporate events and earnings call insights provide some optimism with strategic shifts and improved EBITDA.
To see Spark’s full report on JYNT stock, click here.
More about Joint
Average Trading Volume: 71,312
Technical Sentiment Signal: Sell
Current Market Cap: $139.3M
For a thorough assessment of JYNT stock, go to TipRanks’ Stock Analysis page.